[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590389":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":41,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":33,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":33,"enrollmentInfo":69,"targetDuration":33,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":43,"whyStopped":33,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oxybutynin chloride extended-release tablets 5mg\u002Ftab, 2 tab, PO, qd.","EXPERIMENTAL","Description: Participants in this arm will receive oxybutynin chloride extended-release tablets (10 mg\u002Fday) to assess its effectiveness in improving early continence recovery after robot-assisted radical prostatectomy (RARP) for localized prostate cancer.\n\nIntervention: Drug: Oxybutynin chloride extended-release tablets (10 mg\u002Fday).",[13],"Drug: Oxybutynin chloride extended-release tablets 5mg\u002Ftab, 2 tab, PO, qd.",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","PLACEBO_COMPARATOR","Description: Participants in this arm will receive placebo tablets, identical in appearance to the active drug, to compare the effects of oxybutynin chloride with no active intervention.\n\nIntervention: Placebo: Placebo tablets (identical in appearance to the active drug).",[19],"Drug: Placebo (2 tab), PO, qd.",[21,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","The intervention being studied is oxybutynin chloride extended-release tablets (Oxbu), a muscarinic antagonist that is used to manage overactive bladder symptoms, including urinary incontinence. In this study, it is specifically evaluated for its potential to improve early continence recovery following robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.\n\nThis formulation is an extended-release version of oxybutynin, which allows for a slower, sustained release of the drug over time, ensuring more consistent therapeutic effects with reduced side effects compared to immediate-release formulations. The intervention involves a daily dose of 10 mg, administered as two 5 mg tablets, to assess its impact on postoperative continence recovery.\n\nThe key distinction of this intervention is its focus on improving continence recovery after prostate cancer surgery, specifically through its targeted use in early post-surgical recovery, making it different from othe",[9],[26,27,28],"Oxybutynin Extended-Release Tablets","Oxbu","oxybutynin chloride extended-release tablet",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo (2 tab), PO, qd.","placebo, which is designed to look identical to the active drug but contains no therapeutic ingredient.",[15],null,[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Kuo-How Huang Kuo-How Huang, Professor","CONTACT","+886-2-2312-3456","265952","khhuang123@ntu.edu.tw",[42],{"facility":5,"status":43,"city":44,"state":33,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":33},"RECRUITING","Taipei","100","Taiwan","TW",{"type":49,"coordinates":50},"Point",[51,52],121.52639,25.05306,{"lat":52,"lon":51},{"type":55,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[57],{"name":58,"class":59},"Synmosa Biopharma Corp.","INDUSTRY","100590389","oxybutynin-er-to-promote-early-continence-recovery-after-robotic-prostatectomy-a-randomized-controlled-trial-100590389",false,"NCT06966778","Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy","Inclusion Criteria:\n\n* Diagnosis: Patients with localized prostate cancer who are scheduled to undergo robot-assisted radical prostatectomy (RARP).\n* Age: Participants must be 18 years or older, with no upper age limit.\n* Consent: Participants must provide written informed consent before undergoing any study procedures.\n* Ability to Follow Protocol: Participants must be able to follow the protocol procedures throughout the study.\n\nExclusion Criteria:\n\n* Surgical Complications: Participants who experience surgical complications during or after RARP requiring extraordinary medical or surgical treatment.\n* Other Urinary Conditions: Participants with other diseases causing lower urinary tract symptoms (LUTS) or bladder pain, including:\n* \\- Benign prostatic hyperplasia (BPH), chronic prostatitis, interstitial cystitis, painful bladder syndrome, or urinary tract infection.\n* \\- Overactive bladder or any other condition affecting bladder function.\n* Chronic Medication: Participants with long-term use of medications such as:\n* \\- Alpha-blockers, antimuscarinics, or anticholinergics.\n* Glaucoma: Participants with narrow-angle glaucoma.\n* Urinary Retention: Participants with a history of urinary retention.\n* Gastrointestinal Motility Issues: Participants with severe conditions affecting gastrointestinal motility.\n* Concurrent Medications: Participants who are taking medications that are prohibited by the study protocol (e.g., cholinergic drugs, azole antifungals, smooth muscle relaxants).","MALE","18 Years",{"count":70,"type":71},135,"ESTIMATED","INTERVENTIONAL",[74],"NA","The goal of this double-blind, randomized, placebo-controlled study is to evaluate whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.\n\nThe main questions it aims to answer are:\n\n\\[Does oxybutynin chloride improve continence recovery after RARP compared to a placebo?\\] \\[What are the predictors of continence recovery?\\]\n\nResearchers will compare the treatment group (oxybutynin chloride 10 mg\u002Fday) with the control group (placebo) to assess differences in continence outcomes.\n\nParticipants will:\n\n\\[Take the assigned medication (oxybutynin chloride or placebo) daily for 1-3 months until continence recovery.\\] \\[Complete surveys (e.g., IPSS, IIEF, ICIQ) at several time points post-surgery, including before surgery, 10 days after Foley catheter removal, and up to 12 months.\\] \\[Record any adverse events or concomitant medication use.\\]\n\nSafety and tolerability will be monitored, and statistical analyses will determine the efficacy and predictors of continence. The study adheres to ethical principles, local regulations, and GCP guidelines.",[77,78],"Localized Prostate Cancer","Postoperative Urinary Incontinence",[77,80,81,78,82,83,84,85],"Robot-Assisted Radical Prostatectomy (RARP)","Early Continence Recovery","Oxybutynin Chloride","Extended-Release Tablets","Double-Blind Randomized Study","Placebo-Controlled Trial","2026-03-12",{"date":88,"type":89},"2026-03-16","ACTUAL",{"date":91,"type":89},"2025-09-15",{"date":93,"type":71},"2028-12-31",{"name":5,"class":6},1]